You are here

Home › U.S. authorizes Sobi's drug to treat COVID-19 in high-risk patients › U.S. authorizes Sobi's drug to treat COVID-19 in high-risk patients

U.S. authorizes Sobi's drug to treat COVID-19 in high-risk patients

Primary tabs

U.S. authorizes Sobi's drug to treat COVID-19 in high-risk patients

Thu, 2022-11-10 08:50 — mike kraft
U.S. authorizes Sobi's drug to treat COVID-19 in high-risk patients Sobi North America, a unit of Swedish Orphan Biovitrum AB , said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug for treatment of high-risk hospitalized COVID-19 patients. Reuters Reuters

...

The drug, already approved in the European Union for treating COVID, has been authorized in the United States to treat patients with pneumonia who require oxygen support and those at risk of developing severe respiratory failure.

...

Country / Region Tags: 
Global
Sweden
United States
General Topic Tags: 
COVID-19
Treatments
Disease
Disease Prevention
Government
Health
Pandemics
Public Health
Research
Science
Problem, Solution, SitRep, or ?: 
Situation Report
Groups this Group Post belongs to: 
Global Health
Europe
Medical - global
- Private group -
Workflow history
Revision ID Field name Date Old state New state name By Comment Operations
No state No state
howdy folks